Biomerica, Inc. BMRA 深 滬
等待開盤 02-05 09:30:00 美东时间
2.29
-0.050
-2.14%
華盛通- 最 高2.41
- 今 開2.41
- 成交量 8797股
- 最 低 2.26
- 昨 收 2.34
- 總市值 675.09万
- 52周最高 8.80
- 市盈率 靜 --
- 換手率 0.30%
- 52周最低 2.11
- 委 比 65.99%
- 總股本 294.80万
- 歷史最高 187.12
- 量 比 0.75
- 振 幅 6.41%
- 歷史最低 1.932
- 每 手 1
- 風險率 1.06%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Biomerica reports Q2 results
Biomerica press release (BMRA): Q2 net loss was $1.32 million, compared to $0.95 million in the prior year quarter. Revenue of $1.21M (-26.2% Y/Y). More on Biomerica Seeking Alpha’s Quant Rating on Bi...
01-15 06:19
快讯 | Biomerica公布2026财年第二季度财务业绩
Biomerica Reports Second Quarter Fiscal 2026 Financial Results
01-15 06:17
Biomerica Reports Second Quarter Fiscal 2026 Financial Results
Biomerica reported second quarter 2026 fiscal year results, highlighting a 4% decline in year-to-date operating expenses and a 14.7% improvement in working capital. Key developments include expanding inFoods® IBS commercialization through a collaboration with Henry Schein, launching an AI-backed Trigger Food Navigator, securing a CMS Medicare payment rate of $300 for inFoods® IBS, and receiving regulatory approval for its diagnostic portfolio in ...
01-14 22:17
Biomerica shares are trading higher after the company announced a CMS Medicare payment rate of $300 for its inFoods IBS test.
Biomerica shares are trading higher after the company announced a CMS Medicare ...
2025-12-23 21:22
Biomerica Says CMS Issues Final Pricing Determination For inFoods IBS Test, Establishing National Medicare Payment Rate Of $300 Under CLFS
CMS is the single largest payer for healthcare in the United States, with Medicare responsible for approximately 21% of total healthcare expenditure.The $300 rate will apply to claims approved and paid by Medicare with
2025-12-23 21:21
Biomerica Announces CMS Medicare Payment Rate of $300 for Revolutionary inFoods® IBS Test
CMS has set a national Medicare payment rate of $300 for Biomerica's inFoods® IBS test, effective from January 1, 2026. This decision follows the American Medical Association's approval of a unique CPT® code for the test. The test addresses a significant unmet need for IBS patients, with clinical evidence showing improved symptom management through personalized dietary recommendations. Biomerica plans to use this CMS pricing as a benchmark for ne...
2025-12-23 13:19
Egyptian Drug Authority Authorizes Biomerica’s Complete Screening Test Portfolio
Biomerica's comprehensive portfolio of rapid diagnostic tests has been authorized by Egypt's Drug Authority, enabling mass and individual access to affordable early detection tools for cancers and chronic diseases such as colorectal, breast, prostate cancers, kidney disease, and H. pylori infection. The tests, including EZ Detect™ Colon Disease Test, Aware® Breast Self Exam, Fortel Prostate (PSA) Screening Test, Fortel Kidney Disease (Microalbumi...
2025-12-11 13:08
Biomerica Highlights Clinical Trial Showing inFoods IBS Test Significantly Reduces Symptoms Through Guided Dietary Therapy In The Fall 2025 Issue Of Biotherapeutics Quarterly, A Henry Schein Publication
Publication details large multicenter clinical trial demonstrating significant reductions in IBS symptoms through inFoods IBS guided dietary therapy IRVINE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc.
2025-11-25 21:22
Biomerica’s inFoods® IBS Product Featured in Biotherapeutics Quarterly, a Henry Schein Publication, Highlighting a New Precision Approach for Treating IBS
Biomerica's inFoods® IBS diagnostic-guided therapy demonstrates significant symptom relief in a large, multicenter clinical trial, with 59.6% of patients achieving FDA-defined pain reduction compared to 42.1% in the control group. Particularly effective for IBS-C and IBS-M subtypes, the therapy uses a personalized approach to identify dietary triggers, eliminating only 2-4 foods per patient, offering a practical and sustainable alternative to bro...
2025-11-25 13:19
